Skip to main content
Premium Trial:

Request an Annual Quote

Atossa Genetics Increases Number of Shares, Targeted Proceeds for IPO

NEW YORK (GenomeWeb News) – Atossa Genetics has increased to 1.3 million the number of shares it plans to offer in its initial public offering, the firm said in a document filed with the US Securities and Exchange Commission on Friday.

The Seattle-based firm had previously targeted an offering of 1.2 million shares of its common stock. It also said last week that it needs to raise at least $6.25 million in gross proceeds from the offering in order to get listed on the Nasdaq Capital Market under ticker symbol "ATOS". It previously had said it needed to raise a minimum of $6 million.

The company continues to expect the share price on its IPO to be between $4 and $6. Dawson James Securities is listed as the underwriter on the offering.

Atossa announced earlier this month a marketing deal for its Mammary Aspirate Specimen Cytology Test System, or MASCT, and the acquisition of the assets of intraductal diagnostic and therapeutic company Acueity Healthcare. Last month, it disclosed a deal to provide access to its tests to providers and patients in managed healthcare plan MultiPlan's networks.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.